

# Sarcoptic mange in Australian wildlife

# **Fact Sheet**

October 2025

# **Key points**

- Sarcoptic mange is a parasitic skin disease of mammals, including wildlife, domestic animals and humans, caused by the mite *Sarcoptes scabiei*.
- Sarcoptic mange can cause serious, chronic skin disease and debilitating systemic illness in wildlife. Occasional population level impacts are reported globally, including in Australia.
- Sarcoptic mange has been documented in several native Australian mammal species, with the bare-nosed wombat (*Vombatus ursinus*) the most significantly affected.
- Management of individual sarcoptic mange cases involves either treatment or euthanasia.
- Population management of sarcoptic mange in free-living wildlife is challenging.

# **Aetiology**

Sarcoptic mange, (known as 'scabies' in humans), is a zoonotic, ectoparasitic skin disease caused by infection with *Sarcoptes scabiei* (Family *Sarcoptidae*) <sup>[1, 2]</sup>. *Sarcoptes scabiei* is an obligate parasitic mite that, upon infection of a host, burrows into the stratum corneum (deeper layers of the skin) where it feeds on host cells and tissue fluid <sup>[3]</sup>.

# **One Health implications**

Wildlife and the environment: sarcoptic mange in wildlife can result in significant, chronic, systemic disease, associated with significant debilitation and death. It some cases it can result in local population declines, particularly in isolated, small, naïve or otherwise susceptible host populations <sup>[1]</sup>. Cascading ecosystem effects as a result of sarcoptic mange outbreaks may include disruptions in food webs and vegetation <sup>[4]</sup>. The *in situ* treatment of sarcoptic mange-affected wild animals may have unintended negative impacts on the environment or other species (see <u>Sarcoptic mange</u> treatment in wombats – Environmental Risk Assessment).

**Domestic animals:** spillover from domestic animals is one of the most likely routes of *S. scabiei* introduction into new wildlife species and geographic regions<sup>[5-7]</sup>. Dogs in Aboriginal communities in the north of Australia are commonly reported with *S. scabiei* infections, with implications for transmission to wildlife and humans <sup>[8]</sup>.

**Humans**: disease caused by *S. scabiei* in humans ('scabies') is most often self-limiting <sup>[9]</sup>. Wildlife are unlikely to play a significant role in the occurrence and spread of human scabies. In some Aboriginal communities and aged care facilities in Australia, scabies is a significant public health issue <sup>[10, 11]</sup>.

### **Natural hosts**

Sarcoptes scabiei mites infect a wide range of mammal species, with reports in over 150 mammalian species (30 families from 10 orders) worldwide [12, 13]. Orders with the most species affected include Perissodactyla, Artiodactyla and Diprotodontia [14]. Sarcoptic mange is also reported in Carnivora, Hyracoidea, Insectivora, Lagomorpha, Pinnipedia, Primates and Rodentia. Introduced wildlife species, in particular the European red fox (*Vulpes vulpes*), may play a role as a reservoir and occasional source of *S. scabiei* infection in native Australian mammals [15].

### World distribution

Sarcoptic mange has been documented in wild mammals from every continent except Antarctica [16-20]. Sarcoptic mange is classed as an emerging epidemic disease in wildlife due to increases in host and geographic range [12, 13].

### **Occurrence in Australia**

*Sarcoptes scabiei* was likely not present in Australia prior to colonisation and is thought to have been introduced multiple times in the last 200 years in association with Europeans and their domestic dogs [19, 21].

Sarcoptic mange was first described in bare-nosed wombats (*Vombatus ursinus*) and introduced European red foxes from NSW in 1937 <sup>[22]</sup> and has been reported in native (Table 1) and introduced wildlife across Australia.

**Table 1:** Australian native mammals in which sarcoptic mange has been recorded

Common name	Taxonomic name	Reference
Bare-nosed wombat	Vombatus ursinus	Hartley and English 2005 [23], Skerratt 2005 [24]
Southern hairy-nosed wombat	Lasiorhinus latifrons	Obendorf 1983 [25]
Koala	Phascolarctos cinereus	Obendorf 1983 [25]
Agile wallaby	Macropus agilis	McLelland and Youl 2005 [26]
Swamp wallaby	Wallabia bicolor	Holz et al. 2011 [27]
Bennett's wallaby	Notamacropus rufogriseus	Russell et al. 2024 [28]
Southern brown bandicoot	Isoodon obesulus	Wicks et al. 2007 [29]
Quenda	I. fusciventer	Botten et al. 2022 [15]
Dingo	Canis lupus dingo	Thomson et al. 1992 [30]
Long-nosed potoroo	Potorous tridactylus	Botten et al. 2022 [15]
Common brushtail possum	Trichosurus vulpecula	Botten et al. 2022 [15]
Common ringtail possum	Pseudocheirus peregrinus	Botten et al. 2022 [15]
Tasmanian devil	Sarcophilus harrisii	Russell et al. 2024 [28]

Introduced mammals in which sarcoptic mange has been recorded include European red fox, pig (*Sus scrofa*), horse (*Equus caballus*), and dromedary camel (*Camelus dromedarius*) [1, 2, 31].

The occurrence and impacts of sarcoptic mange in Australian native mammals are highly variable between host species and populations, ranging from isolated reports of affected individuals <sup>[28]</sup> to disease outbreaks <sup>[32]</sup>, sometimes with population-level effects <sup>[33]</sup>.

Sarcoptic mange is most commonly reported in bare-nosed wombats and disease is endemic (regularly occurring) throughout the species' range, with sporadic outbreaks occasionally causing localised population declines or extirpation (localised extinctions) [24, 33, 34]. Sarcoptic mange outbreaks have also occurred in koala (*Phascolarctos cinereus*) and quenda (*Isoodon fusciventer*), and the disease may be becoming regionally endemic in these species [15, 35, 36].

In general, information regarding the occurrence, current species range, and geographic distribution of sarcoptic mange is limited for Australian native wildlife (see *Surveillance and management*).

# **Epidemiology**

The life cycle of *Sarcoptes scabiei* is completed on the host; involves five stages (adults, eggs, larvae, protonymph and tritonymph); and takes two to three weeks to complete. All life stages can also survive in the environment, including adults for up to 19 days in suitable conditions <sup>[37]</sup>.

Sarcoptic mange epidemiology in wildlife is complex and can vary widely between populations and species [1, 14]. Factors that influence epidemiology include:

- Sarcoptes scabiei is a multi-host pathogen that can undergo direct or indirect transmission
- numerous host and environmental factors can impact transmission
- the effects of *S. scabiei* infection, including on host behaviour, reproduction, immune response and mortality rates, can vary between individuals, populations and species
- differences in these host-level effects can, in turn, influence transmission, disease occurrence and persistence.

The epidemiology of sarcoptic mange in most Australian wildlife species requires further clarification and is best understood in bare-nosed wombats. Disease is endemic throughout the bare-nosed wombat's geographic range. Environmental transmission, driven by survival of mites in wombat burrows [38] and burrow-switching behaviours of wombats [39], is thought to be the main route of infection [40]. Environmental conditions play a key role in determining mite survival off-host. The drivers of disease outbreaks that have occasionally been documented in this species remain unclear, however, the ability of mites to survive in wombat burrows appears to be an important factor. Environmental degradation (such as land use change) and climate change can influence sarcoptic mange epidemiology.

Outbreaks of sarcoptic mange have also been described in southern hairy-nosed wombats, koala, and quenda. Seasonality, for example mating and birthing periods, may play a role in mange epidemiology in koalas [35]. Adult male quenda were significantly more likely to be admitted into care with sarcoptic mange than females [15].

# **Clinical signs**

Clinical signs of sarcoptic mange in wildlife can vary significantly between individuals, populations and species and generally include progressive erythema (skin reddening), pruritic dermatitis (intense itching and skin inflammation), alopecia (hair loss) and hyper/parakeratosis (crusting of skin) <sup>[1, 2]</sup>. Signs typically develop within four weeks of infection, and may progress to skin fissuring, behavioural changes (such as increased diurnal activity in affected wombats), disturbance of sight and hearing, weight loss, reduced fertility, local or systemic bacterial infection, sepsis and death <sup>[41]</sup>.

Two distinct disease presentations are recognised, known as alopecic ("ordinary") or parakeratotic ("crusted") mange, depending on the type of host immune response to *S. scabiei* infection. The alopecic form is associated with extensive hair loss but small numbers of mites, spontaneous recovery and low host mortality rates, whereas the parakeratotic form is associated with marked hyperkeratosis, large numbers of mites and host mortality rates of up to 100%.

Parakeratotic mange triggers a cascade of debilitation associated with severe welfare impacts, particularly in bare nosed wombats, but also in other impacted Australian species, such as koala and quenda [15, 35]. Intense itching, skin damage and hair loss cause discomfort, pain, heat loss and sensory disturbance, all of which can impact an animal's physical and psychological well-being. Normal activities such as foraging and sleeping are impeded, reducing the capacity to compensate for secondary protein loss and chronic immune system activation. Weight loss and increased susceptibility to secondary infections are common outcomes, and these further contribute to the development of systemic illness and physical suffering.

# **Diagnosis**

A diagnosis of sarcoptic mange can be made via clinical observation, light microscopy on skin scrapes, PCR on skin swabs or skin scrapes, histological examination of skin biopsies and enzymelinked immunosorbent assays on serum. Morphological or molecular identification of *S. scabiei* mites in the skin are required for definitive diagnosis. Variations in disease stage and clinical presentation may result in false negatives for all diagnostic methods, particularly in early infections or if few mites are present.

The need to capture animals to undertake testing adds challenges to diagnosis in wildlife. Clinical observation with systematic lesion scoring [42] is therefore often used for diagnosis *in situ* (see *Surveillance*) and, in bare-nosed wombats, appears to be sufficiently reliable [42].

# Clinical pathology and pathology

Clinical and gross pathology findings can be highly variable with sarcoptic mange. Clinical pathology is usually non-specific, reflecting inflammatory (hypersensitivity reactions) and infectious processes (secondary bacterial infection), and chronic debilitation (non-regenerative anaemia) [43, 44].

Clinical pathology is often of limited use for informing clinical decisions as changes in haematological or serum biochemistry parameters can be variable, even in severe disease. Non-specific markers of inflammation, such as haptoglobin and serum protein electrophoresis, may be more useful for decision-making in bare-nosed wombats [45].

Histopathology of sarcoptic mange typically includes skin abnormalities (epidermal hyperplasia; hyper/parakeratosis), and systemic changes associated with secondary disease [44, 46, 47].

# **Differential diagnosis**

Differential diagnoses include other causes of pruritic dermatitis and alopecia, including other ectoparasitic infections, atopy, bacterial or fungal dermatitis, and photosensitivity (for example due to ingestion of plant toxins).

### **Treatment**

There is no globally accepted standard treatment regimen for sarcoptic mange in wildlife [48]. The drugs most frequently used include macrocytic lactones (moxidectin, ivermectin) and isooxazoline class ectoparasiticides (fluralaner). Dose rates, administration frequencies and efficacy vary widely between studies, individual animals and species. A systematic review of the treatment of sarcoptic mange in wildlife is available [48].

Comprehensive safety, pharmacokinetic and efficacy data is lacking for treatment options in Australian wildlife. There is uncertainty regarding the most effective protocols for use *in situ*, as well as concerns for animal health and environmental safety [49-51]. Treatments should only be administered by a suitably experienced veterinarian or in compliance with Australian Medicines Veterinary Authority permits.

Treatment of sarcoptic mange in captive and free-living wildlife should include: [41, 50, 52]

- wherever possible, confirmation of diagnosis (morphological or molecular identification of *S. scabiei*) prior to starting treatment
- a pre-treatment assessment by a suitably experienced veterinarian, including evaluation of disease severity (for example, using systematic lesion scoring – see *Diagnosis*) and general health
- euthanasia if disease is advanced or prognosis for recovery is poor. There is published guidance on euthanasia criteria for mange-affected wombats, which could be used to guide decision-making in other wildlife species [45].

Additional considerations for the treatment of free-living animals *in situ* include:

- ensuring accurate delivery of minimum effective doses to target animals only [49]
- ensuring appropriate administration methods to minimise environmental contamination (via spillage or run-off) [53, 54]
- post-treatment monitoring to allow early detection of non-responsive cases and guide additional treatment or euthanasia, as appropriate.

A <u>desktop environmental risk assessment</u> evaluated the potential environmental impacts associated with anti-parasitic treatment of sarcoptic mange in free-ranging wombats and helps to guide further research, inform local risk assessments and promote the development of treatment recommendations for specific situations [51].

Further information on specific treatment regimens for mange in wombats and koalas is available: www.nespthreatenedspecies.edu.au/media/aayh54vj/1-4-4-guidelines-for-treatment-of-australian-wildlife-with-sarcoptic-mange-report-part-1-treatment-guidelines v6.pdf.

The Department of Natural Resources and Environment Tasmania has guidelines on wombat mange management:

https://nre.tas.gov.au/Documents/Wombat%20Mange%20Assessment%20Fact%20Sheet.pdf.

### **Prevention and control**

There are no feasible methods to prevent sarcoptic mange in free-living wildlife.

Individual-level disease control methods involve anti-parasitical treatment or euthanasia, as appropriate. Population-level disease control has been attempted in free-living bare-nosed wombats at the sub-population level but numerous host, treatment and environmental factors make this process extremely challenging, with limited success reported to date [33, 53, 55].

### Research

Further research is required in the following areas:

- surveillance and monitoring to establish sarcoptic mange distribution, prevalence and population-scale impacts on Australian wildlife
- improved understanding of transmission dynamics, including identification of reservoir hosts
- improved understanding of drivers of disease at individual and population levels, including host, pathogen and environmental factors
- improved understanding of host immunological responses
- improved understanding of the genetic differences of *S. scabiei* between host species and how this may affect sarcoptic mange epidemiology
- comprehensive host species-specific safety, pharmacokinetic and efficacy data to support the development of safe and effective treatment regimens.

### Surveillance and management

Sarcoptic mange is not a nationally notifiable animal disease.

Cases detected during general surveillance, in particular reports in new species or geographic areas, are occasionally captured by national surveillance systems. Wildlife Health Australia administers Australia's general wildlife health surveillance system, in partnership with government and nongovernment agencies. Wildlife health data is collected into a national database, the electronic Wildlife Health Information System (eWHIS). Information is reported by a variety of sources including government agencies, zoo-based wildlife hospitals, sentinel veterinary clinics, universities, wildlife rehabilitators, and a range of other organisations and individuals. Targeted surveillance data is also collected by WHA. See the WHA website for more information <a href="https://wildlifehealthaustralia.com.au/Our-Work/Surveillance/eWHIS-Wildlife-Health-Information-System">https://wildlifehealthaustralia.com.au/Our-Work/Surveillance/eWHIS-Wildlife-Health-Information-System</a>.

Ad hoc and systematic surveillance is conducted by wildlife and land managers, wildlife carers and advocacy groups, researchers, farmers, naturalists and biologists:

- WomSAT (wombat survey and analysis tools) is a community-driven program that
  documents wombat sightings, burrow locations, and sarcoptic mange status. Community
  members can document wombat and burrow sightings through the WomSAT website
  (https://womsat.org.au/womsat/default.aspx), or via the mobile phone app.
- The Tasmanian Department of Natural Resources and Environment has a Wombat Working Group which aims to assess the status of wombat populations, and distribution and severity of sarcoptic mange across the state [56], as well as providing advice to the community on treatment of wombats.
- The ACT government has a wombat sarcoptic mange working group involving researchers and community members, with a surveillance app https://survey123.arcgis.com/share/9bf75df45ef7499ba4a38305b3373d29.

We are interested in hearing from anyone with information on this condition in Australian wildlife, including laboratory reports, historical datasets or survey results that could be added to the National Wildlife Health Information System. Negative data are also valuable. If you can help, please contact us at admin@wildlifehealthaustralia.com.au.

# **Acknowledgments**

We are grateful to the people who contributed to this Fact Sheet and would specifically like to thank Lee Skerratt, Alynn Martin, Scott Carver and Eliza Stott.

Wildlife Health Australia recognises the Traditional Custodians of Country throughout Australia. We respectfully acknowledge Aboriginal and Torres Strait Islander peoples' continuing connection to land, sea, wildlife and community. We pay our respects to them and their cultures, and to their Elders past and present.

Please cite this Fact Sheet as: Wildlife Health Australia (2025) "Sarcoptic mange in Australian wildlife – Fact Sheet", published by Wildlife Health Australia, Canberra, available at https://wildlifehealthaustralia.com.au/Resource-Centre/Fact-Sheets

Updated: October 2025

### References and other information

- 1. Pence DB and Ueckermann E (2002) Sarcoptic mange in wildlife. *Revue Scientifique et Technique-Office International des Epizooties*, **21**(2): 385-398
- 2. Bornstein S, Mörner T et al. (2001) *Sarcoptes scabiei* and sarcoptic mange. In 'Parasitic Diseases of Wild Mammals.' (Eds W.M. Samuel, M.J. Pybus and A.A. Kocan) pp. 107-119. (Iowa State University Press: Ames)
- 3. Arlian LG and Morgan MS (2017) A review of *Sarcoptes scabiei*: past, present and future. *Parasites & Vectors*, **10**(1): 297
- 4. Monk JD, Smith JA et al. (2022) Cascading effects of a disease outbreak in a remote protected area. *Ecology Letters*, **25**(5): 1152-1163

- 5. McCarthy P (1960) Transmission of sarcoptic mange from the wild fox (*Vulpes vulpes*) to man and other species in Central Queensland. *Australian Veterinary Journal*, **36**: 479–480
- 6. Perry R (1983) Successful treatment of sarcoptic mange in the common wombat (*Vombatus ursinus*). Australian Veterinary Practitioner, **13**(4): 169
- 7. Skerratt LF (1998) Diseases and parasites of the common wombat *Vombatus ursinus* in the Healesville area of Victoria. In 'Wombats.' (Ed R. Wells, and Pridmore, P) pp. 317-328. (Surrey Beatty & Sons: Chipping Norton, NSW, Australia)
- 8. Smout F, Schrieber L et al. (2017) More bark than bite: Comparative studies are needed to determine the importance of canine zoonoses in Aboriginal communities. A critical review of published research. *Zoonoses Public Health*, **64**(7): 495-504
- 9. Moroni B, Rossi L et al. (2022) Zoonotic episodes of scabies: A global overview. Pathogens, 11(2)
- 10. Andrews RM, Kearns T et al. (2009) A regional initiative to reduce skin infections amongst Aboriginal childrenliving in remote communities of the Northern Territory, Australia. *PLOS Neglected Tropical Diseases*, **3**(11): e554
- 11. Sullivan JR, Watt G et al. (1997) Successful use of ivermectin in the treatment of endemic scabies in a nursing home. *Australasian Journal of Dermatology*, **38**(3): 137-140
- 12. Thompson RC, Kutz SJ et al. (2009) Parasite zoonoses and wildlife: emerging issues. *International Journal of Environmental Research and Public Health*, **6**(2): 678-93
- 13. Tompkins DM, Carver S et al. (2015) Emerging infectious diseases of wildlife: a critical perspective. *Trends in Parasitology*, **31**(4): 149-159
- 14. Escobar LE, Carver S et al. (2022) Sarcoptic mange: An emerging panzootic in wildlife. *Transboundary and Emerging Diseases*, **69**(3): 927-942
- 15. Botten L, Ash A et al. (2022) Characterising a sarcoptic mange epizootic in quenda (*Isoodon fusciventer*). *International Journal for Parasitology: Parasites and Wildlife*, **18**: 172-179
- 16. Zumpt F and Ledger J (1973) Present epidemiological problems of sarcoptic mange in wild and domestic animal. South African Journal of Wildlife Research, **3**(2): 119-120
- 17. Mörner T (1992) Sarcoptic mange in Swedish wildlife. *Revue Scientifique et Technique (International Office of Epizootics)*, **11**(4): 1115-1121
- 18. Kraabøl M, Gundersen V et al. (2015) The taxonomy, life cycle and pathology of *Sarcoptes scabiei* and *Notoedres cati* (Acarina, *Sarcoptidae*): a review in a Fennoscandian wildlife perspective. *Fauna Norvegica*, **35**: 21-33
- 19. Fraser TA, Charleston M et al. (2016) The emergence of sarcoptic mange in Australian wildlife: an unresolved debate. *Parasites & Vectors*, **9**: 1-11
- 20. Old JM, Sengupta C et al. (2018) Sarcoptic mange in wombats—A review and future research directions. *Transboundary and Emerging Diseases*, **65**(2): 399-407
- 21. Fraser TA, Holme R et al. (2019) Expanded molecular typing of *Sarcoptes scabiei* provides further evidence of disease spillover events in the epidemiology of sarcoptic mange in Australian marsupials. *Journal of Wildlife Diseases*, **55**(1): 231-237
- 22. Gray D (1937) Sarcoptic mange affecting wild fauna in New South Wales. *Australian Veterinary Journal*, **13**(4): 154-155
- 23. Hartley M and English A (2005) *Sarcoptes scabei var. wombati* infection in the common wombat (*Vombatus ursinus*). *European Journal of Wildlife Research*, **51**(2): 117-121
- 24. Skerratt LF (2005) *Sarcoptes scabiei*: an important exotic pathogen of wombats. *Microbiology Australia*, **26**(2): 79-81

- 25. Obendorf DL (1983) Causes of mortality and morbidity of wild koalas, *Phascolarctos cinereus* (Goldfuss), in Victoria, Australia. *Journal of Wildlife Diseases*, **19**(2): 123-131
- 26. McLelland DJ and Youl JM (2005) Sarcoptic mange in agile wallabies (*Macropus agilis*) in the Northern Territory. *Australian Veterinary Journal*, **83**(12): 744-745
- 27. Holz PH, Orbell GMB et al. (2011) Sarcoptic mange in a wild swamp wallaby (*Wallabia bicolor*). *Australian Veterinary Journal*, **89**(11): 458-459
- 28. Russell GG, Wilkinson V et al. (2024) Sarcoptic mange in a Tasmanian devil (*Sarcophilus harrisii*) and Bennett's wallaby (*Notamacropus rufogriseus*). *Journal of Wildlife Diseases*, **60**(4): 980-984, 5
- 29. Wicks R, Clark P et al. (2007) Clinical dermatitis in a southern brown bandicoot (*Isoodon obesulus*) associated with the mite *Sarcoptes scabiei*. *Comparative Clinical Pathology*, **16**(4): 271-274
- 30. Thomson P, Rose K et al. (1992) Dingoes in north-western Australia. Wildlife Research, 19(5): 509-603
- 31. Henderson WR (2009) 'Pathogens in vertebrate pests in Australia.' (Invasive Animals Cooperative Research Centre: Canberra)
- 32. Speight K, Whiteley P et al. (2017) Outbreaks of sarcoptic mange in free-ranging koala populations in Victoria and South Australia: a case series. *Australian Veterinary Journal*, **95**(7): 244-249
- 33. Martin AM, Burridge CP et al. (2018) Invasive pathogen drives host population collapse: effects of a travelling wave of sarcoptic mange on bare-nosed wombats. *Journal of Applied Ecology*, **55**(1): 331-341
- 34. Carver S, Lewin ZM et al. (2023) Density independent decline from an environmentally transmitted parasite. *Biology Letters*, **19**(8): 20230169
- 35. Young ET, Phalen D et al. (2024) A retrospective epidemiological study of sarcoptic mange in koalas (*Phascolarctos cinereus*) using wildlife carer admission records. *International Journal for Parasitology:* Parasites and Wildlife, **24**: 100955
- 36. Young ET, McKelson J et al. (2024) Pharmacokinetics and safety of topical fluralaner in koalas (*Phascolarctos cinereus*). *International Journal for Parasitology: Parasites and Wildlife*, **25**: 100999
- 37. Arlian L, Runyan R et al. (1984) Survival and infestivity of *Sarcoptes scabiei* var. *canis* and var. *hominis. Journal of the American Academy of Dermatology*, **11**(2): 210-215
- 38. Browne E, Driessen MM et al. (2021) Environmental suitability of bare-nosed wombat burrows for *Sarcoptes scabiei. International Journal for Parasitology: Parasites and Wildlife*, **16**: 37-47
- 39. Skerratt LF, Martin RW et al. (1998) Sarcoptic mange in wombats. *Australian Veterinary Journal*, **76**(6): 408-10
- 40. Ringwaldt E, Brook B et al. (2023) Host, environment, and anthropogenic factors drive landscape dynamics of an environmentally transmitted pathogen: sarcoptic mange in the bare-nosed wombat. *Journal of Animal Ecology*, **92**(9): 1786-1801
- 41. Campbell-Ward M (2019) Wombats. In 'Current Therapy in Medicine of Australian Mammals ' (Eds L. Volegnest and T. Portas) pp. 515–523. (CSIRO: Melbourne)
- 42. Fraser TA, Martin A et al. (2018) Comparative diagnostics reveals PCR assays on skin scrapings is the most reliable method to detect *Sarcoptes scabiei* infestations. *Veterinary Parasitology*, **251**: 119-124
- 43. Skerratt LF (2003) Clinical response of captive common wombats (*Vombatus ursinus*) infected with *Sarcoptes scabiei var. wombati. Journal of Wildlife Diseases*, **39**(1): 179-192
- 44. Ruykys L, Breed B et al. (2013) Effects and treatment of sarcoptic mange in southern hairy-nosed wombats (*Lasiorhinus latifrons*). *Journal of Wildlife Diseases*, **49**(2): 312-320
- 45. Wilkinson V, Richards SA et al. (2024) Non-specific markers of inflammation in bare-nosed wombats (*Vombatus ursinus*) with sarcoptic mange. *Frontiers in Veterinary Science*, **11**: 1403221
- 46. Skerratt LF (2003) Cellular response in the dermis of common wombats (*Vombatus ursinus*) infected with *Sarcoptes scabiei var. wombati. Journal of Wildlife Diseases*, **39**(1): 193-202

- 47. Skerratt LF, Middleton D et al. (1999) Distribution of life cycle stages of *Sarcoptes scabiei* var *wombati* and effects of severe mange on common wombats in Victoria. *Journal of Wildlife Diseases*, **35**(4): 633-646
- 48. Rowe ML, Whiteley PL et al. (2019) The treatment of sarcoptic mange in wildlife: a systematic review. *Parasites & Vectors*, **12**: 1-14
- 49. Mounsey K, Harvey RJ et al. (2022) Drug dose and animal welfare: important considerations in the treatment of wildlife. *Parasitology Research*, **121**(3): 1065-1071
- 50. Skerratt L, Death C et al. (2021) Guidelines for the treatment of Australian wildlife with sarcoptic mange, Part 1- Treatment guidelines, NESP Threatened Species Recovery Hub Project. Available from: <a href="https://www.nespthreatenedspecies.edu.au/media/aayh54vj/1-4-4-guidelines-for-treatment-of-australian-wildlife-with-sarcoptic-mange-report-part-1-treatment-guidelines\_v6.pdf">https://www.nespthreatenedspecies.edu.au/media/aayh54vj/1-4-4-guidelines-for-treatment-of-australian-wildlife-with-sarcoptic-mange-report-part-1-treatment-guidelines\_v6.pdf</a>
- 51. Arcadis (2024) Sarcoptic mange treatment in wombats: environmental risk assessment. Available from: <a href="https://wildlifehealthaustralia.com.au/Portals/0/ResourceCentre/BiosecurityMgmt/ERA">https://wildlifehealthaustralia.com.au/Portals/0/ResourceCentre/BiosecurityMgmt/ERA</a> Sarcoptic mange treatment wombats.pdf
- 52. Department of Natural Resources and Environment Tasmania (2022) Wombat Mange Assessment Fact Sheet, Department of Natural Resources and Environment Tasmania. Available from: <a href="https://nre.tas.gov.au/Documents/Wombat%20Mange%20Assessment%20Fact%20Sheet.pdf">https://nre.tas.gov.au/Documents/Wombat%20Mange%20Assessment%20Fact%20Sheet.pdf</a>
- 53. Leary TN, Kaye L et al. (2025) Treatment and monitoring of a high-density population of bare-nosed wombats for sarcoptic mange. *PLoS One*, **20**(10): e0332138
- 54. Martin AM, Richards SA et al. (2019) Population-scale treatment informs solutions for control of environmentally transmitted wildlife disease. *Journal of Applied Ecology*, **56**(10): 2363-2375
- 55. Leary T, Kaye L et al. (2017) Outcomes and lessons learnt from the pilot sarcoptic mange treatment program of common wombats *Vombatus ursinus* at Bents Basin State Conservation Area. In 'The Strategic Wombat Conference'. Wombat Protection Society of Australia: Penrith, NSW
- 56. Driessen MM, Dewar E et al. (2021) Conservation status of common wombats in Tasmania I: incidence of mange and its significance. *Pacific Conservation Biology*, **28**(2): 103-114

### To provide feedback on Fact Sheets

Wildlife Health Australia welcomes your feedback on Fact Sheets. Please email <a href="mailto:admin@wildlifehealthaustralia.com.au">admin@wildlifehealthaustralia.com.au</a>. We would also like to hear from you if you have a particular area of expertise and are interested in creating or updating a WHA Fact Sheet. A small amount of funding is available to facilitate this.

#### **Disclaimer**

This Fact Sheet is managed by Wildlife Health Australia for information purposes only. Information contained in it is drawn from a variety of sources external to Wildlife Health Australia. Although reasonable care was taken in its preparation, Wildlife Health Australia does not guarantee or warrant the accuracy, reliability, completeness, or currency of the information or its usefulness in achieving any purpose. It should not be relied on in place of professional veterinary or medical consultation. To the fullest extent permitted by law, Wildlife Health Australia will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on information in this Fact Sheet. Persons should accordingly make and rely on their own assessments and enquiries to verify the accuracy of the information provided.



Find out more at wildlifehealthaustralia.com.au Email: admin@wildlifehealthaustralia.com.au Or call +61 2 9960 6333